Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anqi Lin

Showing results (61-70 of 200) with videos related to

Pageof 20
Sort By:
Frontiers in Cell and Developmental Biology|December 28, 2020
Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell CancerYueming Zhang, Anqi Lin, Yonghe Li, et al.
Frontiers in Immunology|October 4, 2021
TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung CancerAnqi Lin, Hongman Zhang, Hui Meng, et al.
Chemistry, an Asian Journal|July 31, 2022
Microsphere-containing Hydrogel Scaffolds for Tissue EngineeringShihao Zhang, Anqi Lin, Ziwei Tao, et al.
Cancer Innovation|December 21, 2023
Mutations in the DNA polymerase binding pathway affect the immune microenvironment of patients with small-cell lung cancer and enhance the efficacy of platinum-based chemotherapyAnqi Lin, Weiming Mou, Lingxuan Zhu, et al.
Immunotherapy|August 16, 2023
<i>CACNA1C</i> mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanomaYushan Huang, Anqi Lin, Tianqi Gu, et al.
International Journal of Surgery (London, England)|May 10, 2024
Advancing generative artificial intelligence in medicine: recommendations for standardized evaluationAnqi Lin, Lingxuan Zhu, Weiming Mou, et al.
Polymers|September 6, 2016
PEG-chitosan hydrogel with tunable stiffness for study of drug response of breast cancer cellsFei-Chien Chang, Ching-Ting Tsao, Anqi Lin, et al.
International Journal of Cancer|October 24, 2022
Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysisTianqi Gu, Aimin Jiang, Chaozheng Zhou, et al.
Genes & Diseases|March 19, 2026
Renal adverse events in EGFR-TKI treatment: Comprehensive characterization of clinical patterns and molecular underpinningsHuili Xiao, Anqi Lin, Wentao Xu, et al.
European Journal of Pharmacology|May 31, 2025
Advancements in RNA-targeted therapies for renal cell carcinomaHanzhong Zhang, Anqi Lin, Chen Cai, et al.
Pageof 20

Showing results (61-70 of 200) with videos related to

Sort By:
Pageof 20
Frontiers in Cell and Developmental Biology|December 28, 2020
Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell CancerYueming Zhang, Anqi Lin, Yonghe Li, et al.
Frontiers in Immunology|October 4, 2021
TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung CancerAnqi Lin, Hongman Zhang, Hui Meng, et al.
Chemistry, an Asian Journal|July 31, 2022
Microsphere-containing Hydrogel Scaffolds for Tissue EngineeringShihao Zhang, Anqi Lin, Ziwei Tao, et al.
Cancer Innovation|December 21, 2023
Mutations in the DNA polymerase binding pathway affect the immune microenvironment of patients with small-cell lung cancer and enhance the efficacy of platinum-based chemotherapyAnqi Lin, Weiming Mou, Lingxuan Zhu, et al.
Immunotherapy|August 16, 2023
<i>CACNA1C</i> mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanomaYushan Huang, Anqi Lin, Tianqi Gu, et al.
International Journal of Surgery (London, England)|May 10, 2024
Advancing generative artificial intelligence in medicine: recommendations for standardized evaluationAnqi Lin, Lingxuan Zhu, Weiming Mou, et al.
Polymers|September 6, 2016
PEG-chitosan hydrogel with tunable stiffness for study of drug response of breast cancer cellsFei-Chien Chang, Ching-Ting Tsao, Anqi Lin, et al.
International Journal of Cancer|October 24, 2022
Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysisTianqi Gu, Aimin Jiang, Chaozheng Zhou, et al.
Genes & Diseases|March 19, 2026
Renal adverse events in EGFR-TKI treatment: Comprehensive characterization of clinical patterns and molecular underpinningsHuili Xiao, Anqi Lin, Wentao Xu, et al.
European Journal of Pharmacology|May 31, 2025
Advancements in RNA-targeted therapies for renal cell carcinomaHanzhong Zhang, Anqi Lin, Chen Cai, et al.
Pageof 20